Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death. The efficacy and safety of tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, in patients with MASH and moderate or severe fibrosis is unclear. METHODS: We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks. The primary end point was resolution of MASH without worsening of fibrosis at 52 weeks. A key secondary end point was an improvement (decrease) of at least one fibrosis stage without worsening of MASH. RESULTS: Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group. The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons). The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42). The most common adverse events in the tirzepatide groups were gastrointestinal events, and most were mild or moderate in severity. CONCLUSIONS: In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis. Larger and longer trials are needed to further assess the efficacy and safety of tirzepatide for the treatment of MASH. (Funded by Eli Lilly; SYNERGY-NASH ClinicalTrials.gov number, NCT04166773.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary outcome for all three studies was resolution of fatty liver disease without worsening of fibrosis, and significant improvements were noted.”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [83]
In the citing paper
“tirzepatide led to an increased proportion of participants reaching an improvement in fibrosis by at least one stage.83”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [83]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [29]
In the citing paper
“Other recent analyses have revealed survodutide, tirzepatide, and retatrutide to each significantly reduce liver fat with no evidence of worsening in markers of liver fibrosis.77, 78, 79”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [79]
In the citing paper
“tirzepatide also increased the proportion of patients achieving at least one-stage fibrosis improvement without MASH worsening (approximately 51–55% vs. 30% with placebo).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [224]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationVilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citation
Cited by
Items 501–600 of 999
Early Adoption and Prescribing Patterns of Resmetirom: A Multi‐Institutional National Analysis
Solpari, K., Gouda, Z., Saggese, A., Buckholz, A. P., Sharaiha, R. Z., Kumar, S. R., & Kushner, T. (2026) · Liver International · doi:10.1111/liv.70580 · Cited by 2
YANG, Z., Tong, W., Zhang, K., & Guo-xin, H. (2026) · Liver Research · doi:10.1016/j.livres.2026.03.001 · Cited by 3
Aghemo, A., Armandi, A., Bugianesi, E., Cabibbo, G., Carbone, M., D’Ambrosio, R., Dalbeni, A., Cola, S. D., Gasbarrini, A., Germani, G., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.02.014 · Cited by 4
Self-citationAlves, G. A. M., Teranishi, M., Majumdar, R., Khan, F., Dodeja, M., Ortega, A. C. T. D. C. G., Acerboni, M., Arachchige, A. S. P. M., & James, F. (2026) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.70048 · Cited by 4
Benny, O., Agarwal, A., Alecock, H., Subramani, R. G., Pawar, A., Shams, Z., Kermansaravi, M., Pouwels, S., Yang, W., Gerald, C., et al. (2026) · Pancreatology · doi:10.1016/j.pan.2026.03.021 · Cited by 6
Zhao, S., Tian, F., Yu, L., Li, Z., Hou, J. Y., Wei, Y., Cui, H., Cui, S., & Ma, X. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04326-w · Cited by 4
Kehar, M., Germán, A. G. A., Pandey, A., Mysore, K. R., Narang, A., Pandurangi, S., Suri, A., Whitehead, B. A., Aqul, A. A., & Duro, D. (2026) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.70367 · Cited by 2
Genetic risk of steatotic liver disease: Pathogenesis, prognosis, and implications for treatment
Kozlitina, J., Romeo, S., & Hobbs, H. H. (2026) · Hepatology · doi:10.1097/hep.0000000000001758 · Cited by 2
Mahmod, M., Dennis, A., Lian, J., Langford, C., Rahimi, K., & Wamil, M. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10629-z · Cited by 2
Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes
Panou, T., Gouveri, E., Popovic, D. S., Papazoglou, D., & Παπάνας, Ν. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01865-5 · Cited by 2
Integrating Alcohol Use Into MASLD Care: A Practical Guide for Diabetes and Obesity Care Teams
Alexopoulos, A., & Cusi, K. J. (2026) · Diabetes Care · doi:10.2337/dci26-0019 · Cited by 3
Vettor, R., Petroni, M. L., Dotan, I., Lalazar, G., Haluzík, M., Spearman, C. W., Dave, J. A., Abaalkhail, F. A., Abusnana, S., Alshehri, A. A., et al. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10027-8 · Cited by 6
Almazan, E., Choi, J., Kamath, T., Nguyen, V. H., Przybyszewski, E. M., Song, J., Carroll, A., Michta, M., Simon, T. G., & Chung, R. T. (2026) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000004048 · Cited by 2
Albusta, N., Isa, S., & Alrahma, H. N. S. (2026) · Diseases · doi:10.3390/diseases14050173 · Cited by 8
The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities
Henney, A. E., & Wilding, J. P. H. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.84 · Cited by 4
Wang, X., Lu, G., Zhou, Y., & Zhao, G. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02891-7 · Cited by 4
André‐Dumont, S., & Lanthier, N. (2026) · Liver International · doi:10.1111/liv.70680 · Cited by 3
Soares, A. O., Loli, D. A. C., de Carvalho, G. R., Delfino, V. D. A., & Bignardi, P. R. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10059-0 · Cited by 2
Khalil, S. M., Al‐Sharif, L., Diaz, I., & de Souza, M. H. G. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-10057-x · Cited by 3
Sairaj, R. T., Liang, A., Castillo, Y. C., Madera, M. D. F., Medina, J., Díaz, T. A. M., Monar, G. F., Chintamaneni, S., Cruz, C. S., Advani, R., et al. (2026) · Gastro Hep Advances · doi:10.1016/j.gastha.2026.101040 · Cited by 3
Jarvis, H., Brennan, P., Casanovas, T., Casler, K., Desai, M., Evans, P. H., Dillon, J. F., Grattagliano, I., Hallsworth, K., Hebditch, V., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00015-4 · Cited by 5
Esteatosis hepática metabólica en el síndrome cardio-reno-metabólico: la «H» silenciada
Crespo, J., Iruzubieta, P., de Vega, T., & Calleja, J. L. (2026) · Medicina Clínica · doi:10.1016/j.medcli.2026.107536 · Cited by 2
Noureddin, M., Dunn, W., Patil, R., Desai, D., Puskoor, R., Shin, J., To, D., BELL, A. C., Lee, D. R., Lin, Y.-H., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00130-5 · Cited by 2
MAFLD/MASLD: Past, Present, and Future
Wong, V. W. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70619 · Cited by 2
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity
Jastreboff, A. M., Kaplan, L. M., Davies, M. J., Wilding, J. P. H., Ahmad, N. N., Murray, M. H., Du, Y., Makarova, N., Giblin, K. A., Schloot, N. C., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2604169 · Cited by 9
Forlano, R., Malik, H., Mullish, B. H., Yee, M. S., Izzi‐Engbeaya, C. N., & Manousou, P. (2024) · Liver international communications. · doi:10.1002/lci2.86 · Cited by 2
Paradigm shift in steatotic liver disease (SLD): from NAFLD to MASLD
Yoneda, M., Kobayashi, T., Iwaki, M., Wada, N., Nogami, A., Takahashi, H., & Nakajima, A. (2024) · Kanzo · doi:10.2957/kanzo.65.420 · Cited by 2
Self-citationCharting New Territories in Obesity Management- Traditional Techniques to Tirzepatide
Fareed, A., Ghanem, L., Vaid, R., Iftikhar, Z., Rehman, A. U., Sarwar, A., & Asif, M. I. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.004 · Cited by 3
Truscello, E., Wang, S., Young, J., Sebastiani, G., Walmsley, S. L., Hull, M., Cooper, C., & Klein, M. B. (2024) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiae487 · Cited by 3
Cao, W., Jiang, T., Deng, W., Wang, S., Li, X., Zhang, Z., Zhang, L., Yao, L., Chang, M., Liu, R., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1384927 · Cited by 3
Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease
Stefan, N., & Roden, M. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2312-0452 · Cited by 2
Lemasters, J. J., & Zhong, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15260-3.00026-0 · Cited by 3
Huang, R., Zhang, C., Mo, X., & Rao, H. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003417 · Cited by 5
Leite, A. R., Dias, J., Godinho, T., Correia-Chaves, J., Borges‐Canha, M., Lourenço, I. M., Leite-Moreira, A. F., & Neves, J. S. (2024) · Endocrinology Insights · doi:10.1159/000541442 · Cited by 5
Desai, C., Lohani, S., Sharma, A., Schwartz, L., Gujjula, S. R., Baskar, A., Baskar, U., Baskar, S., & Vasikaran, A. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002153 · Cited by 3
Wong, Y. J., & Goh, G. B. (2025) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-051 · Cited by 2
Incretins for management of obesity and obstructive sleep apnea
Hu, X., Yee, B. J., Phillips, C. L., Chapman, J. L., & Grunstein, R. R. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2513516 · Cited by 2
Wang, S., Fan, D., Yao, Q., & Sun, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16580 · Cited by 3
Sardà, H., Genua, I., & Miñambres, I. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.106951 · Cited by 3
Taha, M. M. E., Abdelwahab, S. İ., Oraibi, O., Madkhali, M. A., Alhazmi, A., Jeraiby, M., Abdullah, S. M., Farasani, A. M., Moshi, J. M., Khamjan, N. A., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04574-1 · Cited by 3
Metabolic Dysfunction Associated to Steatotic Liver Disease: A Review
Torres, J. V. D., Guerrero, V. R. V., Gómez, J. P. V., Miranda, F. J. P., Álvarez, L. R. O., Insignares, J. D. L., Mares, M., Ortiz, H. M. R., & Mendoza‐Torres, E. (2025) · Metabolic Syndrome and Related Disorders · doi:10.1177/15578518251382048 · Cited by 4
Dual Agonists for Management of Metabolic Dysfunction–Associated Steatohepatitis
Kanwal, F. (2024) · New England Journal of Medicine · doi:10.1056/nejme2406487 · Cited by 2
Sherker, A. H., & Hoofnagle, J. H. (2025) · Hepatology · doi:10.1097/hep.0000000000001264 · Cited by 2
GLP-1 receptor agonists and MASLD in diabetes: A promising path?
Pennisi, G., Petta, S., Maggio, V., & Rizzo, M. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109041 · Cited by 3
Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages
Aquino, J. B. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1792423 · Cited by 1
D’Alessio, D. A., & Kahn, S. E. (2024) · Diabetes · doi:10.2337/dbi24-0046 · Cited by 1
Lee, J., & Shin, M. (2025) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2025.7.e2 · Cited by 2
Piťhová, P. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.009 · Cited by 1
Clinical trajectories in liver cirrhosis: An evidence-based reappraisal for the internist
Zampino, R., Patauner, F., & Durante‐Mangoni, E. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.04.028 · Cited by 3
Alicic, R. Z., & Neumiller, J. J. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2024.12.003 · Cited by 1
Diagnose und Therapie der MASLD
Horn, P., & Tacke, F. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01896-3 · Cited by 1
Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis
Romero‐Gómez, M., Escalada, J., Noguerol, M., Pérez, A., Carretero, J., Crespo, J., Mascort, J. J., Aguilar, I., Tinahones, F. J., Cañones, P., et al. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastre.2025.502442 · Cited by 6
Mondal, S., Chowdhury, A. S., Deb, R., & Sanyal, D. (2025) · Diabetology International · doi:10.1007/s13340-025-00833-x · Cited by 2
Glucagon-like peptide-1 receptor analogues and beyond: emerging obesity pharmacotherapies
Abburi, K., Melson, E., Miras, A. D., & Papamargaritis, D. (2025) · Panminerva Medica · doi:10.23736/s0031-0808.25.05339-x · Cited by 1
Current and Future Implications of Weight Loss Drugs on Liver Disease
Bussetty, A., Shah, N., Chandler, T. M., Ghattu, M., & Kesavarapu, K. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.06.005 · Cited by 1
Year in Review: Selection of Best Papers in Gastroenterology and Hepatology 2024
Camilleri, M., & Dellon, E. S. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.06.001 · Cited by 1
Screening for MASLD in patients with type 2 diabetes: is an early diagnosis a good diagnosis?
Nwoguh, C. A., Byrne, C. D., Reinson, T., & Buchanan, R. M. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2546597 · Cited by 2
Challenging the Dogma: Reversal of End-Stage Liver Fibrosis with Tirzepatide in MASH Cirrhosis
Nguyen, T.-D., Lam-Himlin, D. M., Lizaola‐Mayo, B., & Chascsa, D. M. H. (2025) · Transplantology · doi:10.3390/transplantology6030025 · Cited by 1
Walton, S., Guirguis, E. H., Mack, K., & Assil, R. (2025) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaf251 · Cited by 1
Vilarrasa, N., & Pellitero, S. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.107184 · Cited by 2
ApoJ and apoL1 as novel determinants of MASH: a cross-sectional study
Cai, Z., Najib, S., Núñez‐Sánchez, M. Á., Martínez‐Sánchez, M. A., García-Melgares, C., Viguerie, N., Rossell, J., Julve, J., Croyal, M., Oliveira, A. R., et al. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02733-0 · Cited by 1
Metabolic and Alcohol-Associated
Sandella, R., & Rinella, M. E. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.09.003 · Cited by 2
Pugliese, N., Spertino, M., Mercurio, M., Ciardullo, S., Perseghin, G., Hassan, C., Vettor, R., Petta, S., & Aghemo, A. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.10.018 · Cited by 2
Lee, S. H., Kim, J. H., Lee, S. R., Lee, B. S., Kim, K. H., Jun, D. W., Kim, C. S., & Kang, K. A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1707492 · Cited by 1
Will GLP-1 Agonists Weaken the Links between Obesity and Cancer?
Brennan, D. J., & Lynch, L. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0991 · Cited by 1
GLP-1-based therapies for obesity: Impact on comorbidities or obesity-related diseases
Vilarrasa, N., & Pellitero, S. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.107184 · Cited by 1
Peptide hormones and bile acids shaping immune tolerance of the liver: implications and applications
van Niekerk, G., Kumpanenko, Y., Degryse, J., Fevery, J., & Dallmeier, K. (2025) · Protein & Cell · doi:10.1093/procel/pwaf096 · Cited by 1
Choi, J., Fulop, D., Nguyen, V. H., Przybyszewski, E. M., Song, J., Carroll, A., Michta, M., Almazan, E., Simon, T. G., & Chung, R. T. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2025.0825 · Cited by 12
Brown, E. E., Bilson, J., Alam, U., Goff, L. M., Kemp, G. J., Pfeiffer, A. F. H., Weickert, M. O., Umpleby, A. M., Byrne, C. D., & Cuthbertson, D. J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112997 · Cited by 2
A narrative review on tirzepatide’s therapeutic potential in glycemic control and cardioprotection
Thiriveedi, M., Domingo, F. S., Yates, H., Baddam, S., Beblawy, R. E., Nimmana, B., & Patel, S. (2025) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000004055 · Cited by 7
Acuña, P., ALBHAISI, O. A., Idalsoaga, F. J., Alkhouri, N., Noureddin, M., Díaz, L. A., & Arab, J. P. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.61 · Cited by 2
Sanyal, A. J., Ratziu, V., Hajji, Y., Magnanensi, J., Deledicque, S., Majd, Z., Hum, D. W., Staels, B., Connelly, M. A., Francque, S., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000844 · Cited by 2
Self-citationPosition Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250615i · Cited by 2
Posicionamento sobre a Saúde Cardiometabólica ao Longo do Ciclo de Vida da Mulher – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250615 · Cited by 5
Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025
de Oliveira, G. M. M., de Almeida, M. C. C., Valério, C. M., Giuffrida, F. M. A., Espíndola, L. N., Izar, M. C. D. O., Marques-Santos, C., Freire, C. M. V., Albuquerque, C. J. D. M., Chagas, A. C. P., et al. (2025) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.61622/rbgo/2025rbgo200 · Cited by 2
Nowak, M. A., Dennis, A., Thomaides-Brears, H. B., Mouchti, S., Alkhouri, N., & Cuthbertson, D. J. (2025) · Liver international communications. · doi:10.1002/lci2.70029 · Cited by 1
Tirzepatide vs. semaglutide: clinical decision-making in the GLP-1 landscape
Mondoh, A., Crotty, M., & le Roux, C. W. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2601060 · Cited by 3
Drug treatment of MASH from none to (too) many options?
Lonardo, A., & Weiskirchen, R. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001378 · Cited by 2
Nonga, D., Chaves, E. A., Pandurangi, S., Hartjes, K. T., Chu, C., & Flores, A. (2025) · Current Treatment Options in Pediatrics · doi:10.1007/s40746-025-00356-2 · Cited by 1
Post-transplant Metabolic Complications: A Contemporary Overview
Vögelin, M., & Selzner, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-07072-2_29 · Cited by 1
Management of metabolic dysfunction and cardiovascular risk in patients with MASLD
Danpanichkul, P., Blaney, H. L., Perelli, J., Huerta, P., Idalsoaga, F. J., Arrese, M. A., Arab, J. P., Loomba, R. S., & Díaz, L. A. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.32 · Cited by 3
Self-citationLuca, M. D., Verdoliva, R., Lombardi, A., & Giorgio, A. (2026) · Gastroenterology Insights · doi:10.3390/gastroent17010007 · Cited by 1
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
Patel, K. M., Jnawali, C., Zhang, J., Marsden, J. E., Bays, C., & Schreiner, A. D. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.013 · Cited by 1
Wang, M., Jiang, Y.-N., Li, P.-P., & Wu, Y.-J. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s565093 · Cited by 2
Warden, B. A., Duell, P. B., Bucheit, J. D., & Purnell, J. Q. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.013 · Cited by 1
Belančić, A., Antza, C., Poutachidis, A., Palaska, S., Gkrinia, E. M. M., Faour, A. K., Şener, Y. Z., Şener, S., & Sultana, R. (2026) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70492 · Cited by 1
A transdisciplinary framework for managing metabolic dysfunction associated steatotic liver disease
Kouser, S., Sharma, S. V., Bhanu, A., Kukkupuni, S. K., & Vishnuprasad, C. N. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1767844 · Cited by 2
Cardiometabolic and Diabetes Management in Older Adults
Marion, W., & Neeland, I. J. (2026) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2025.12.005 · Cited by 1
Mohamed, M. A., Taha, M. M. M. I., & Ibrahim, M. M. M. R. (2026) · ASIDE Gastroenterology · doi:10.71079/aside.gi.022626448 · Cited by 2
Consensus statement on obesity management in liver transplantation candidates
Pacheco, D., Vinaixa, C., de Gordejuela, A. G. R., Alcázar, C. F., Seoane, R. M. Á., Delgado, J. B., Mizrahi, D. C., Díaz‐Zorita, B., Santiago, R. F., Suárez, Y. J. F., et al. (2026) · Updates in Surgery · doi:10.1007/s13304-025-02473-x · Cited by 1
Metabolic Liver Disease Beyond the Liver
Gastaldelli, A., Tacke, F., & Holleboom, A. G. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.12.003 · Cited by 1
Metabolische Lebererkrankungen bei Adipositas
Horn, P., & Tacke, F. (2026) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2722-1114 · Cited by 1
Srimanus, K., Damrongmanee, A., Ukarapol, N., Chattipakorn, N., & Chattipakorn, S. C. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168218 · Cited by 2
Transplant hepatology: New epidemiology and indications
Ferrarese, A., Vivian, L. M., Martino, L., Burra, P., & Germani, G. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.01.231 · Cited by 3
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1445 · Cited by 1
Troshina, E. A., Suplotova, L. A., Dzgoeva, F. K., Ekusheva, E. V., Vyuchnova, E. S., Okovityi, S. V., Bakulin, I. G., Бакулина, Н. В., Karonova, T. L., Vagapova, G. R., et al. (2026) · Problems of Endocrinology · doi:10.14341/probl13737 · Cited by 1
Han, X., Ai, X., Sun, Y., Chen, S., Zhao, X., & You, H. (2026) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000003081 · Cited by 1
A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
Lee, A.-H., & Holmes-Walker, D. J. (2026) · Healthcare · doi:10.3390/healthcare14060734 · Cited by 2
Obesity, metabolic health status, and adverse outcomes in men and women
Ananda, R. A., Solomon, B. D., Nicholls, S. J., & Ray, K. K. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101556 · Cited by 2
Metadata
- Authors
- Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., Brouwers, B., Robins, D. A., Nikooie, A., Bunck, M. C., Haupt, A., & Sanyal, A. J.
- Affiliations
- University of California San Diego (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-25
- Volume
- 391
- Issue
- 4
- Pages
- 299-310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399461049
- Cited by
- 1,005
- References
- 37
- Citations by year
- 2026: 458 · 2025: 433 · 2024: 114
- FWCI
- 306.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, nonalcoholic steatohepatitis, liver fibrosis, GIP/GLP-1 receptor agonist, fibrosis regression, dose-response relationship, liver biopsy, non-alcoholic fatty liver disease, obesity, type 2 diabetes, weight loss, drug safety, adverse events, liver complications, hepatocellular carcinoma, liver cirrhosis
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Fatty Liver, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.